Itolizumab Treatment of Acute GVHD: Positive Results.

Transplant anti-host disease (GVHD) is a complication of transplanting tissue and organs from other people's bodies.
GVHD is generally associated with bone marrow transplantation, but this concept can also be used in transplants in other tissues.
GVHD is the behavior of the immune cells in the graft that treat the host as a foreign body and therefore attack the host cell.
Equillium, a clinical-stage biotech company that is developing the research drug itolizumab for the treatment of severe autoimmune and inflammatory diseases, today released positive interim data from the Ib Open Label Clinical Trial (EQUATE Study).
to date, the overall tolerance of itolizumab in both dose groups has been good, with 5 out of 7 patients achieving complete remission (CR) on the 29th day.
EQUATE study is evaluating the effectiveness and safety of the first-line treatment of patients with severe GVHD in the combination of itolizumab.
in the first two dose groups of the Ib open label section, 71% of patients reached CR on the 29th day.
in the first queue of 0.4 mg / kg doses, 2 out of 4 patients reached CR.
in the second batch of patients, the dose was 0.8 mg / kg, all 3 patients received CR, CR rate and ORR were 100%.
, these CRes occur early in itolizumab treatment, and all patients reach CR within the first 15 days of treatment.
so far, Itolizumab has been well tolerated.
based on a comprehensive review of the security data for both queues, the Independent Data Monitorrecommend recommended that the dose increase study be conducted as planned in the third queue (1.6 mg / kg) of the EQUATE study.
.